Boston Scientific Corporation

Background

Company Name	Boston Scientific Corporation
Stock Symbol	BSX
Class Period	July 23, 2025 to February 03, 2026
Lead Plaintiff Motion Deadline	May 04, 2026

Submit Your Information

If you suffered a loss on your Boston Scientific Corporation investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filling out this form mean you have joined any lawsuit.

First Name*

Middle Initial

Last Name*

Email*

Phone*

If representing a Corporation, Trust, Partnership or other entity, Name of Entity

If representing an Entity, Position at Entity

Mailing Address

City

State/Province

ZIP/Postal Code

Country

Are you a current or former employee of the company?

Did you purchase any shares before July 23, 2025?

Shares Purchased

Number of Shares	Buy Date	Price Per Share	Add
Purchased quantity	Purchased month Purchased day Purchased year

Shares Sold

Number of Shares	Sell Date	Price Per Share	Add
	Sold month Sold day Sold year

Additional Comments

Background

On February 4, 2026, Boston Scientific reported fourth quarter and full year 2025 results, including a disappointment in U.S. Electrophysiology sales, and issued fiscal 2026 guidance — including for the first half of 2026 — that fell below expectations. The Company attributed the results to slower than expected market growth and increased competition, despite prior statements describing the EP business as “growing” and asserting it had “a very good understanding of what competition we will face and in what time frame.”

On this news, Boston Scientific’s stock price fell $16.12, or approximately 17.6%, from $91.62 per share on February 3, 2026, to $75.50 per share on February 4, 2026.

Submit Your Information